Monitoring Atrial Fibrillation in Patients with Silent Brain Lesions

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to investigate the incidence of atrial fibrillation (AF) in patients aged 65 and older who have clinically silent brain ischemic lesions. Participants will undergo continuous rhythm monitoring through a subcutaneously implanted cardiac monitor to assess the cumulative incidence of AF over 24 months. The study seeks to clarify the relationship between silent brain infarctions and the occurrence of AF, comparing the rates of AF diagnosis in these patients to those with cryptogenic acute ischemic stroke. The findings could enhance understanding of AF's role in silent strokes and improve patient management.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age

  * ≥ 65 years
  * ≥ 50 years AND one the following:

    * NT-proBNP \>400 pg/mL
    * Left atrial ventricular index \>42 ml/m2 or left atrial diameter \>46 mm
    * Covert infarctions with cortical involvement in more than one vascular territory (left carotid territory, right carotid territory, vertebrobasilar territory)
* Written informed Consent
* Any clinically silent ischemic lesions of the brain parenchyma detected on neuroimaging defined according to established criteria as either:

  * Diffusion weighted imaging (DWI) positive lesions: Focus of restricted diffusion (high DWI signal and low apparent diffusion coefficient value) occurring in either white or gray matter, located in the cerebrum, cerebellum, or brain stem AND not satisfying the diagnostic criteria for multiple sclerosis OR
  * Cavitatory Lesions: ≥ 3 mm in size that follow cerebro-spinal fluid on all sequences that are slit or wedge shaped with an irregular margin AND NOT longitudinally aligned with perforating vessels or with a multiple, bilateral symmetrical distribution OR
  * T2 weighted (T2W) hyperintense/T1 weighted (T1W) hypointense lesions:

    * Focal lesion with high T2W signal and low T1W signal that have prior evidence of restricted diffusion; OR
    * Present within cortical gray matter or deep gray matter nuclei OR
    * A lesion that is new, compared with an MRI performed within 3 months OR
    * T2W hyper/T1W hypointense lesions in the white matter, which are discontinuous but associated with the classic confluent periventricular T2 intense change of leukoaraiosis (Fazekas ≥2) AND NOT satisfying the diagnostic criteria for multiple sclerosis or with a significant patient history of severe trauma, radiation, drug toxicity, or carbon monoxide poisoning

Exclusion Criteria:

* History of AF or atrial flutter
* Patients with a history of symptoms compatible with an AIS, covert neurological deficits are allowed.
* Cardiac implantable electronic devices (pacemaker, implantable cardiac defibrillator (ICD), implantable cardiac monitor (ICM))
* Indication for cardiac implantable electronic device implantation (pacemaker, ICD, ICM)
* History of or indication for major cardiac surgery or transcutaneous aortic valve implantation
* Indication for permanent oral anticoagulation
* Contraindication for permanent oral anticoagulation
* Projected life expectancy of less than 2 years
* Active intra- or extracranial high-grade malignancy
* Patient is already included in another clinical trial that will affect the objectives of this study
* Patient's lack of accountability, inability to appreciate the nature, meaning and consequences of the study and to formulate his/her own wishes correspondingly
* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc.
* Known or suspected non-compliance, drug or alcohol abuse

Where it's running

• Universitätsspital Graz
  Graz, Austria Recruiting
• Centre hospitalier universitaire vaudois (CHUV)
  Lausanne, Canton of Vaud, Switzerland Recruiting
• University Hospital Basel
  Basel, Switzerland Recruiting
• Inselspital Bern
  Bern, Switzerland Recruiting
• Kantonsspital St.Gallen
  Sankt Gallen, Switzerland Recruiting
• Universitätsspital Zurich
  Zurich, Switzerland Recruiting

Study contacts

• Principal investigator: Laurent Roten, PD Dr. med. — Inselgruppe AG
• Study coordinator: Laurent Roten, PD Dr. med.
• Email: laurent.roten@insel.ch
• Phone: +41 31 632 52 63

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Understanding silent strokes and their risk factors

  This study looks at silent strokes in patients to see what risk factors might help prevent future strokes and improve treatment.

  Recruiting at 2 sites Insel Gruppe AG, University Hospital Bern · Tours and 1 other locations · NCT05685069

• Biomarkers That Signal Silent Strokes in High-Risk Cardiac Procedures

  This study tests whether blood biomarkers NSE and NFLs can predict silent brain injuries and later cognitive problems in adults having high-risk transcatheter heart procedures.

  Recruiting Aristotle University Of Thessaloniki · Thessaloniki · NCT07844850

• Diagnosing neurocognitive complications during surgery using EEG

  This study is testing if using EEG during surgery can help doctors spot early signs of cognitive problems, like delirium, in adults having non-cardiac surgeries.

  Recruiting Federal Research and Clinical Centre of Intensive Care Medicine and Rehabilitology · Moscow, Moscow Oblast · NCT06545786

• Comparing anticoagulants for patients with atrial fibrillation and severe kidney disease

  This study is testing whether different blood-thinning medications can help people with atrial fibrillation and severe kidney disease stay healthier and avoid complications.

  Recruiting at 2 sites Phase 4 Hospital Sirio-Libanes · Salvador, Estado de Bahia and 5 other locations · NCT06402851

• Ablation and Isolation for Persistent Atrial Fibrillation Treatment

  This study is testing a new two-step treatment for long-lasting atrial fibrillation to see if it works better than the standard method and helps patients need fewer medications.

  Recruiting Barts & The London NHS Trust · London · NCT06165510

• Personalized ablation strategies for atrial fibrillation

  This study is testing personalized treatment plans for people with persistent atrial fibrillation to see if tailored catheter ablation can improve their heart rhythm and treatment success.

  Recruiting Barts & The London NHS Trust · London · NCT05633303

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.